Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02481830 · ClinicalTrials.gov registry record · Phase 3
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 569
- Enrollment target
NCT02481830 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 569 participants.
The verdict
NCT02481830, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 569 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed SCLC.
Interventions
- DRUG Nivolumab
- DRUG Topotecan
- DRUG Amrubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 569 participants |
| Start Date | 2015-09-14 |
| Est. Completion | 2022-08-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02481830
The ClinicalTrials.gov registry entry for NCT02481830 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 569 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT02481830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02481830 about?
NCT02481830 is a clinical study titled "Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer". The purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed SCLC.
What is the current status of trial NCT02481830?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 569 participants. The study started on 2015-09-14. Estimated completion is 2022-08-30.
What interventions are being tested in trial NCT02481830?
The interventions under investigation include: Nivolumab (DRUG), Topotecan (DRUG), Amrubicin (DRUG).
Who is sponsoring clinical trial NCT02481830?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.